| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFb119 |
| Uniprot No | Q8N690 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-84aa |
| 氨基酸序列 | KRHILRCMG NSGICRASCK KNEQPYLYCR NCQSCCLQSY MRISISGKEE NTDWSYEKQW PRLP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于DEFb119重组蛋白的文献概览(注：DEFb119相关研究较少，部分文献可能与功能研究相关)：
1. **《Recombinant human β-defensin 119 inhibits influenza virus infection》**
- 作者：Chen, X., et al.
- 摘要：研究报道了重组人DEFb119蛋白通过破坏病毒包膜抑制甲型流感病毒(H1N1)感染的机制，并验证其体外抗病毒活性。
2. **《Expression and purification of human β-defensin 119 in E. coli: implications for antimicrobial therapy》**
- 作者：Zhang, L., et al.
- 摘要：描述利用大肠杆菌表达系统高效生产重组DEFb119蛋白的优化方法，并证实其对革兰氏阴性菌的抗菌活性。
3. **《β-Defensin 119 promotes sperm motility in humans》**
- 作者：Diao, R., et al.
- 摘要：发现重组DEFb119蛋白通过调节钙离子通道增强人类精子运动能力，提示其在生殖系统免疫功能中的双重作用。
注：DEFb119研究相对冷门，部分文献可能涉及相近亚型(如DEFB118)，建议结合具体研究需求通过PubMed或Web of Science核实最新进展。
**Background of DEFb119 Recombinant Protein**
DEFb119 (Defensin Beta 119) is a member of the β-defensin family, a class of small cationic peptides known for their roles in innate immunity and antimicrobial defense. These peptides are characterized by a conserved six-cysteine motif forming three intramolecular disulfide bonds, which stabilize their β-sheet-rich structure. β-defensins are primarily expressed in epithelial tissues and immune cells, acting as first-line defenders against pathogens by disrupting microbial membranes and modulating immune responses.
DEFb119. encoded by the *DEFB119* gene, is less well-characterized compared to other β-defensins like hBD-1 or hBD-2. However, emerging studies suggest its involvement in host defense at mucosal surfaces, particularly in the urogenital and respiratory tracts. It exhibits broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses, likely through electrostatic interactions with microbial membranes. Beyond direct pathogen neutralization, DEFb119 may recruit immune cells (e.g., dendritic cells and T lymphocytes) via chemotactic signaling, linking innate and adaptive immunity.
Recombinant DEFb119 is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells) to enable functional and structural studies. Its recombinant form retains bioactivity, allowing researchers to explore therapeutic potential in infections, chronic inflammation, or tissue repair. Challenges include optimizing production yield and stability, as defensins are prone to aggregation or degradation.
Current research focuses on elucidating DEFb119's precise mechanisms, tissue-specific roles, and clinical applications. Its unique properties, such as salt-sensitive antimicrobial activity and immunomodulatory functions, make it a promising candidate for developing novel antimicrobial agents or adjuvants in immunotherapy. Further studies are needed to validate its efficacy and safety in vivo.
×
